TY - JOUR
AU - Schiff, Peter B.
AB - 502 Review article Encouse B. Golden, Silvia C. Formenti and Peter B. Schiff In parallel with the discovery of the taxanes, our killing with an associated improvement in clinical understanding of the molecular underpinnings that responses. Numerous studies have shown that taxanes comprise the classic biologic principles of fractionated radiosensitize tumor cells directly and/or indirectly radiotherapy has rapidly evolved over the past half century. by perturbing the tumor microenvironment in a Early studies have implicated DNA as the primary target time-dependent and dose-dependent manner. for radiation-induced lethality. More recently, however, the Herein, the impact of taxanes on radiobiological tenets molecular biology involved in radiosensitization of tumor as a mode of radiosensitizing tumor cells and their cells has been unveiled. Specifically, factors associated clinical implications are reviewed. Anti-Cancer Drugs with DNA damage and cell killing, collectively known as the 25:502–511  c 2014 Wolters Kluwer Health | Lippincott ‘four Rs’ of radiobiology, including (r)eassortment of tumor Williams & Wilkins. cells into the radiosensitive phases of the cell cycle (G /M), Anti-Cancer Drugs 2014, 25:502–511 (r)eoxygenation of hypoxic areas within a tumor, (r)epair Keywords: abraxane, docetaxel, paclitaxel, radiation sensitizer, taxane of sublethal DNA damage, and (r)epopulation of surviving tumor cells, have 
TI - Taxanes as radiosensitizers
JF - Anti-Cancer Drugs
DO - 10.1097/CAD.0000000000000055
DA - 2014-06-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/taxanes-as-radiosensitizers-g8I50Lo3bI
SP - 502–511-502&ndash
EP - ndash;511-502–511
VL - 25
IS - 5
DP - DeepDyve
ER -